Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam™ technology

Cancer Journal

Volumn 7, Issue 3, 2001, Pages 219-227

  Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Cytarabine; DepoFoam ; Leptomeningeal metastases; Lympnomatous meningitis; Morphine; Multivesicular liposomes; Neoplastic meningitis

Indexed keywords

AMIKACIN; ANALGESIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUPIVACAINE; CIDOFOVIR; CYTARABINE; FLUOROURIDINE; GANCICLOVIR CYCLIC PHOSPHATE; GENTAMICIN; INSULIN; INTERLEUKIN 2; LIPOSOME; METHOTREXATE; MORPHINE; RECOMBINANT ALPHA INTERFERON; TOBRAMYCIN; ZALCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CELL CYCLE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG TISSUE LEVEL; HUMAN; INJECTION; KERATITIS; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; RETINITIS; SURGICAL INFECTION; SUSTAINED RELEASE FORMULATION;

ANALGESICS, OPIOID; ANTI-BACTERIAL AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIVIRAL AGENTS; CYTARABINE; DELAYED-ACTION PREPARATIONS; HUMANS; METHOTREXATE; MORPHINE;

EID: 0035715353     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Preparation of multivesicular liposomes
2. Multivesicular liposome (DepoFoam™) technology for the sustained delivery of insulin-like growth factor-I (IGF-I)
3. Extended CSF cytarabine exposure following intrathecal administration of DTC 101
4. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam™
5. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101): A phase I study
6. Multivesicular liposomes containing cytarabine for slow-release SC administration
7. Extended-release formulation of morphine for subcutaneous administration
8. Pharmacokinetics of an extended-release human interferon alpha-2b formulation
9. A slow-release methotrexate formulation for intrathecal chemotherapy
10. Multivesicular liposomes containing bleomycin for subcutaneous administration
11. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis
12. Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes
13. Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy
14. Intratumoral chemotherapy with multivesicular liposomes containing cytosine arabinoside
15. Multivesicular liposomes containing 1-beta-D-arabinofuranosylcytosine for slow-release intrathecal therapy
16. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases
17. Treatment of carcinomatous meningitis (CM) with intra-CSF cytarabine-lipid particle injection (Depocyt™) vs. methotrexate
18. Sustained-release methotrexate for intracavitary chemotherapy
19. An extended-release formulation of methotrexate for subcutaneous administration
20. Multivesicular liposomes: Sustained release of the antimetabolite cytarabine in the eye
21. Sustained release of the antimetabolite 5-fluorouridine-5′-monophosphate by multivesicular liposomes
22. Filtering surgery in owl monkeys treated with the antimetabolite 5-fluorouridine 5′-monophosphate entrapped in multivesicular liposomes
23. Liposome suppression of proliferative vitreoretinopathy: Rabbit model using antimetabolite encapsulated liposomes
24. Retinal toxicity of the antimetabolite 5-fluorouridine 5′-monophosphate administered intravitreally using multivesicular liposomes
25. Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes
26. Evaluation of retinal toxicity and liposome encapsulation of the anti-CMV drug 2′-nor-cyclic GMP
27. Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC
28. Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis
29. Tobramycin liposomes: Single subconjunctival therapy of pseudomonal keratitis
30. Fibrin-enmeshed tobramycin liposomes: Single application topical therapy of Pseudomonas keratitis
31. Pharmacokinetics of DepoFoam™ gentamicin delivery system and effect on soft tissue infection
32. Soft tissue infection prophylaxis with gentamicin encapsulated in multivesicular liposomes: Results from a prospective, randomized trial
33. Lipid-based slow-release formulation of amikacin sulfate reduces foreign body-associated infections in mice
34. Sustained-release morphine for epidural analgesia in rats
35. DepoBupivacaine for prolonged epidural analgesia
36. Pharmacokinetics (PK) of DepoCyt™ after intrathecal administration for the treatment of leptomeningeal metastases (LM)
37. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT)
38. A multivesicular lipid-based sustained release system for the delivery of therapeutic proteins
39. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors
40. Cytosine arabinoside cerebrospinal fluid kinetics
41. The effect of 1-β-D-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells
42. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy
43. Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma
44. Extremely prolonged continuous intraperitoneal infusion of cytosine arabinoside
45. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study
46. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer
47. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based intraperitoneal chemotherapy: Lessons learned from a Gynecologic Oncology Group phase 11 trial of intraperitoneal cisplatin and recombinant alpha-interferon
48. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: A phase Il study
49. Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer
50. Fine needle percutaneous intratumoral chemotherapy under ultrasound guidance: A feasibility study
51. Effects of intralesional versus IP administration of cisplatin on squamous cell carcinoma of mice
52. Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children
53. Glaucoma filtering surgery with 5-fluorouracil
54. 5-Fluorouracil and glaucoma filtering surgery: II. A pilot study
55. Fluorouracil for the treatment of massive periretinal proliferation
56. Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy
57. Restricted transport of 3′-azido-3′-deoxythymidine and dideoxynucleosides through the blood-brain barrier
58. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: Use of an intravitreal device
59. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: A randomized controlled clinical trial
60. CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration
61. Pharmacokinetics of morphine in cerebrospinal fluid and plasma after epidural administration in man
62. The influence of drug polarity on the absorption of opioid drugs into CSF and subsequent cephalad migration following lumbar epidural administration: Application to morphine and pethidine
63. Pharmacokinetics of different epidural sites of morphine administration
64. Pharmacokinetics of epidural morphine and meperidine in humans